Immix Biopharma (Nasdaq: IMMX)
Chief Commercial Officer
Immix Biopharma (Nasdaq: IMMX), Los Angeles, California, United States, 90079
Chief Commercial Officer
Immix Biopharma, Inc.
Los Angeles, CA / Hybrid
Our 3 Core Values
Intelligence
Integrity
Initiative
Our mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting!
What You’ll Do:
The Chief Commercial Officer (CCO) plays a critical role in shaping the commercial future of our company. The CCO will propose, gain alignment for, and lead execution of commercial strategy for NXC-201 and subsequent pipeline products.
Devise a recommended commercial strategy including pre-launch, launch and commercialization plans to maximize the value of NXC-201. Develop and gain consensus for pre-launch, launch and commercialization plans with recommended resource allocation.
Build a high‑performing customer‑focused commercial organization including US sales, customer marketing, market access and pricing, patient and provider services, commercial operations,
Skills and Experience We Look For:
Minimum of 10 years of commercial experience in the biotech or pharmaceutical industry, with a proven track record in cell therapy or oncology. Previous experience in launch / commercialization of CAR‑T therapies
Bachelor's degree in Business, Marketing, Life Sciences, or a related field. MBA or advanced degree preferred.
Strong leadership, team‑building and collaboration skills with experience leading cross‑functional teams. Ability to cultivate a team‑oriented culture in a supportive fast‑growth and learning environment.
Ability to think strategically and develop innovative solutions to complex problems.
Excellent verbal and written communication skills with the ability to effectively engage and influence stakeholders at all levels.
Ability to thrive in a fast‑paced, dynamic environment.
Strong team orientation and passion for continuous self‑development.
About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. Our lead candidate is sterically‑optimized BCMA‑targeted chimeric antigen receptor T (CAR‑T) cell therapy NXC‑201 with a “digital filter” that filters out non‑specific activation. NXC‑201 is being evaluated in the U.S. multi‑center study for relapsed/refractory AL Amyloidosis NEXICART‑2 (NCT06097832), with a registrational design. NEXICART‑2 primary endpoint was met at interim results presented at ASCO 2025. NXC‑201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
#J-18808-Ljbffr
Our 3 Core Values
Intelligence
Integrity
Initiative
Our mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting!
What You’ll Do:
The Chief Commercial Officer (CCO) plays a critical role in shaping the commercial future of our company. The CCO will propose, gain alignment for, and lead execution of commercial strategy for NXC-201 and subsequent pipeline products.
Devise a recommended commercial strategy including pre-launch, launch and commercialization plans to maximize the value of NXC-201. Develop and gain consensus for pre-launch, launch and commercialization plans with recommended resource allocation.
Build a high‑performing customer‑focused commercial organization including US sales, customer marketing, market access and pricing, patient and provider services, commercial operations,
Skills and Experience We Look For:
Minimum of 10 years of commercial experience in the biotech or pharmaceutical industry, with a proven track record in cell therapy or oncology. Previous experience in launch / commercialization of CAR‑T therapies
Bachelor's degree in Business, Marketing, Life Sciences, or a related field. MBA or advanced degree preferred.
Strong leadership, team‑building and collaboration skills with experience leading cross‑functional teams. Ability to cultivate a team‑oriented culture in a supportive fast‑growth and learning environment.
Ability to think strategically and develop innovative solutions to complex problems.
Excellent verbal and written communication skills with the ability to effectively engage and influence stakeholders at all levels.
Ability to thrive in a fast‑paced, dynamic environment.
Strong team orientation and passion for continuous self‑development.
About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. Our lead candidate is sterically‑optimized BCMA‑targeted chimeric antigen receptor T (CAR‑T) cell therapy NXC‑201 with a “digital filter” that filters out non‑specific activation. NXC‑201 is being evaluated in the U.S. multi‑center study for relapsed/refractory AL Amyloidosis NEXICART‑2 (NCT06097832), with a registrational design. NEXICART‑2 primary endpoint was met at interim results presented at ASCO 2025. NXC‑201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
#J-18808-Ljbffr